Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
Sacks
Frank M
FM
Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA. fsacks@hsph.harvard.edu
D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D018570:Risk Assessment; D040242:Risk Reduction Behavior; D014481:United States / Q000453:epidemiology
D000960:Hypolipidemic Agents; D011345:Fenofibrate